Director GEMAYEL GEORGES sold SUPERNUS PHARMACEUTICALS, INC. ($SUPN) shares on the open market twice in the last 365 days, totaling about $1 million. His most recent sale occurred on March 6, 2026. These SUPN insider sales rank 4,916th among 11,678 individual insiders, below the average sale amount of $8.6 million across 6.37 transactions on average. Georges made no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 5, 2026 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | GEMAYEL GEORGES | Director | S | Common Stock | 10000 | $53.71 | 28,159.0000 | 56,552,741 | 26.21% | 0.02% |
| March 6, 2026 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | GEMAYEL GEORGES | Director | M | Director Stock Option (Right to Buy) | 7905 | $0.00 | 0.0000 | 56,552,741 | 100.00% | 0.01% |
| March 6, 2026 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | GEMAYEL GEORGES | Director | S | Common Stock | 8787 | $53.00 | 27,277.0000 | 56,552,741 | 24.37% | 0.02% |
| March 6, 2026 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | GEMAYEL GEORGES | Director | M | Common Stock | 7905 | $25.30 | 36,064.0000 | 56,552,741 | 28.07% | 0.01% |
| Feb. 24, 2026 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | GEMAYEL GEORGES | Director | A | Common Stock | 4475 | $0.00 | 38,159.0000 | 56,552,741 | 13.29% | 0.01% |
| Feb. 24, 2026 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | GEMAYEL GEORGES | Director | D | Restricted Stock Unit | 4475 | $0.00 | 0.0000 | 56,552,741 | 100.00% | 0.01% |
| Feb. 23, 2026 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | GEMAYEL GEORGES | Director | M | Director Stock Option (Right to Buy) | 15000 | $0.00 | 0.0000 | 56,552,741 | 100.00% | 0.03% |
| Feb. 23, 2026 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | GEMAYEL GEORGES | Director | M | Common Stock | 15000 | $12.98 | 33,684.0000 | 56,552,741 | 80.28% | 0.03% |
| Feb. 18, 2026 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | GEMAYEL GEORGES | Director | A | Restricted Stock Unit | 2989 | $0.00 | 2,989.0000 | 56,552,741 | 9999.99% | 0.01% |
| Feb. 18, 2026 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | GEMAYEL GEORGES | Director | A | Director Stock Option (Right to Buy) | 4977 | $0.00 | 4,977.0000 | 56,552,741 | 9999.99% | 0.01% |
| Sept. 16, 2025 | Disc Medicine, Inc. | $IRON | GEMAYEL GEORGES | Not found | A | Stock Option (Right to Buy) | 1000 | $0.00 | 1,000.0000 | 34,569,042 | 9999.99% | 0.00% |
| June 11, 2025 | Disc Medicine, Inc. | $IRON | GEMAYEL GEORGES | Not found | A | Stock Option (Right to Buy) | 10000 | $0.00 | 10,000.0000 | 34,569,042 | 9999.99% | 0.03% |
| Feb. 22, 2025 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | GEMAYEL GEORGES | Director | A | Common Stock | 5369 | $0.00 | 18,684.0000 | 55,958,537 | 40.32% | 0.01% |
| Feb. 22, 2025 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | GEMAYEL GEORGES | Director | D | Restricted Stock Units | 5369 | $0.00 | 0.0000 | 55,958,537 | 100.00% | 0.01% |
| Feb. 19, 2025 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | GEMAYEL GEORGES | Director | A | Restricted Stock Unit | 4475 | $0.00 | 4,475.0000 | 55,958,537 | 9999.99% | 0.01% |
| Feb. 19, 2025 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | GEMAYEL GEORGES | Director | A | Director Stock Option (Right to Buy) | 7296 | $0.00 | 7,296.0000 | 55,958,537 | 9999.99% | 0.01% |
| Nov. 8, 2024 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | GEMAYEL GEORGES | Director | M | Common Stock | 10787 | $11.46 | 24,102.0000 | 56,016,350 | 81.01% | 0.02% |
| Nov. 8, 2024 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | GEMAYEL GEORGES | Director | M | Director Stock Option (Right to Buy) | 10787 | $0.00 | 0.0000 | 56,016,350 | 100.00% | 0.02% |
| Nov. 8, 2024 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | GEMAYEL GEORGES | Director | S | Common Stock | 10787 | $36.30 | 13,315.0000 | 56,016,350 | 44.76% | 0.02% |
| Nov. 7, 2024 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | GEMAYEL GEORGES | Director | M | Common Stock | 14213 | $11.46 | 27,528.0000 | 56,016,350 | 106.74% | 0.03% |
| Nov. 7, 2024 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | GEMAYEL GEORGES | Director | M | Director Stock Option (Right to Buy) | 14213 | $0.00 | 10,787.0000 | 56,016,350 | 56.85% | 0.03% |
| Nov. 7, 2024 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | GEMAYEL GEORGES | Director | S | Common Stock | 14213 | $36.62 | 13,315.0000 | 56,016,350 | 51.63% | 0.03% |
| Sept. 13, 2024 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | GEMAYEL GEORGES | Director | M | Director Stock Option (Right to Buy) | 10000 | $0.00 | 25,000.0000 | 55,506,828 | 28.57% | 0.02% |
| Sept. 13, 2024 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | GEMAYEL GEORGES | Director | S | Common Stock | 10000 | $31.33 | 13,315.0000 | 55,506,828 | 42.89% | 0.02% |
| Sept. 13, 2024 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | GEMAYEL GEORGES | Director | M | Common Stock | 10000 | $11.46 | 23,315.0000 | 55,506,828 | 75.10% | 0.02% |
| Sept. 13, 2024 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | GEMAYEL GEORGES | Director | S | Common Stock | 3886 | $31.33 | 13,315.0000 | 55,506,828 | 22.59% | 0.01% |
| June 12, 2024 | Disc Medicine, Inc. | $IRON | GEMAYEL GEORGES | Not found | A | Stock Option (Right to Buy) | 10000 | $0.00 | 10,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 23, 2024 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | GEMAYEL GEORGES | Director | A | Common Stock | 3886 | $0.00 | 17,201.0000 | 55,506,828 | 29.19% | 0.01% |
| Feb. 23, 2024 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | GEMAYEL GEORGES | Director | D | Restricted Stock Unit | 3886 | $0.00 | 0.0000 | 55,506,828 | 100.00% | 0.01% |
| Feb. 22, 2024 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | GEMAYEL GEORGES | Director | A | Director Stock Option (Right to Buy) | 8252 | $0.00 | 8,252.0000 | 55,506,828 | 9999.99% | 0.01% |
| Feb. 22, 2024 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | GEMAYEL GEORGES | Director | A | Restricted Stock Units | 5369 | $0.00 | 5,369.0000 | 55,506,828 | 9999.99% | 0.01% |
| June 9, 2023 | Disc Medicine, Inc. | $IRON | GEMAYEL GEORGES | Director | A | Stock Option (Right to Buy) | 7136 | $0.00 | 7,136.0000 | 0 | 9999.99% | 0.00% |
| Feb. 23, 2023 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | GEMAYEL GEORGES | Director | A | Director Stock Option (Right to Buy) | 6293 | $0.00 | 6,293.0000 | 61,679,800 | 9999.99% | 0.01% |
| Feb. 23, 2023 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | GEMAYEL GEORGES | Director | A | Restricted Stock Units | 3886 | $0.00 | 3,886.0000 | 61,679,800 | 9999.99% | 0.01% |
| Feb. 22, 2023 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | GEMAYEL GEORGES | Director | A | Common Stock | 3882 | $0.00 | 13,315.0000 | 61,679,800 | 41.15% | 0.01% |
| Feb. 22, 2023 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | GEMAYEL GEORGES | Director | D | Restricted Stock Units | 3882 | $0.00 | 0.0000 | 61,679,800 | 100.00% | 0.01% |
| Dec. 29, 2022 | Disc Medicine, Inc. | $IRON | GEMAYEL GEORGES | Director | A | Stock Option (Right to Buy) | 7000 | $0.00 | 7,000.0000 | 0 | 9999.99% | 0.00% |